Periadjuvant Pembrolizumab Improves EFS in Resectable Melanoma
Periadjuvant pembrolizumab may improve outcomes over adjuvant pembrolizumab alone in patients with resectable stage III-IV melanoma, a phase 2 study suggests.
Periadjuvant pembrolizumab may improve outcomes over adjuvant pembrolizumab alone in patients with resectable stage III-IV melanoma, a phase 2 study suggests.
A novel method of treating immune checkpoint inhibitor-associated myocarditis may decrease the risk of death from myotoxicity.
Researchers described possible associations between Kaposi sarcoma and Koebner phenomenon in a case series of patients with lesions appearing after a prior cutaneous injury.
Investigators in Spain developed an algorithm for diagnosing melanomas that had good diagnostic accuracy and was easier to perform than other diagnostic algorithms.
Researchers compared all-cause and melanoma-specific mortality in patients aged 15 to 39 years and 40 to 64 years with advanced melanoma.
Nonablative fractional laser-treated patients had lower rate of subsequent facial keratinocyte carcinoma development.
Researchers sought to determine feasibility of methods for encouraging improved skin cancer self-examination among survivors of childhood cancers.
Lower percentage of individuals seen with history of past or present melanoma, any type of skin cancer among regular users.
Primary tumor ulceration, head/neck location, and Breslow thickness >4 mm predict worse survival in teens.
Prostate cancer incidence increased from 2014 to 2019; large decrease in cervical cancer incidence linked to HPV vaccine.